Loading...

AddLife

OM:ALIF BTA B
Snowflake Description

Mediocre balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ALIF BTA B
OM
SEK5B
Market Cap
  1. Home
  2. SE
  3. Pharmaceuticals & Biotech
Company description

AddLife AB (publ), together with its subsidiaries, provides products, services, and advisory services to private and public sector life science companies in Sweden, Finland, Denmark, Norway, and internationally. The last earnings update was 9 days ago. More info.


Add to Portfolio Compare Print
ALIF BTA B Share Price and Events
7 Day Returns
-
OM:ALIF BTA B
4.2%
SE Life Sciences
2.3%
SE Market
1 Year Returns
-
OM:ALIF BTA B
42.2%
SE Life Sciences
1.6%
SE Market
ALIF BTA B Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
AddLife (ALIF BTA B) - - - - - -
SE Life Sciences 4.2% 1.2% 10.8% 42.2% 67.1% 155%
SE Market 2.3% 6.2% 9.3% 1.6% 16.2% 18.9%
1 Year Return vs Industry and Market
  • No trading data on ALIF BTA B.
  • No trading data on ALIF BTA B.
Price Volatility
ALIF BTA B
Industry
5yr Volatility vs Market
Related Companies

ALIF BTA B Value

 Is AddLife undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of AddLife to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data    Our calculation method for this is changing soon.

Below are the data sources, inputs and calculation used to determine the intrinsic value for AddLife.

OM:ALIF BTA B Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.3%
Perpetual Growth Rate 10-Year SE Government Bond Rate 0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for OM:ALIF BTA B
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year SE Govt Bond Rate 0.4%
Equity Risk Premium S&P Global 9.6%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 0.73
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.729 (1 + (1- 22%) (16.53%))
0.823
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.82
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.43% + (0.823 * 9.57%)
8.3%

Discounted Cash Flow Calculation for OM:ALIF BTA B using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for AddLife is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.

OM:ALIF BTA B DCF 1st Stage: Next 5 year cash flow forecast
2019 2020 2021 2022 2023
Levered FCF (SEK, Millions) 31.69 37.68 44.46 52.02 60.34
Source Est @ 18.9% Est @ 18.9% Est @ 18%, capped from 18.9% Est @ 17%, capped from 18.9% Est @ 16%, capped from 18.9%
Present Value
Discounted (@ 8.3%)
29.26 32.12 35.00 37.81 40.50
Present value of next 5 years cash flows SEK174.69
OM:ALIF BTA B DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2023 × (1 + g) ÷ (Discount Rate – g)
= SEK60.34 × (1 + 0.43%) ÷ (8.3% – 0.43%)
SEK770.23
Present Value of Terminal Value = Terminal Value ÷ (1 + r)5
= SEK770.23 ÷ (1 + 8.3%)5
SEK516.92
OM:ALIF BTA B Total Equity Value
Calculation Result
Total Equity Value = Present value of next 5 years cash flows + Terminal Value
= SEK174.69 + SEK516.92
SEK691.61
Equity Value per Share
(SEK)
= Total value / Shares Outstanding
= SEK691.61 / 24.49
SEK28.24
OM:ALIF BTA B Discount to Share Price
Calculation Result
Value per share (SEK) From above. SEK28.24
Current discount Discount to share price of SEK209.00
= -1 x (SEK209.00 - SEK28.24) / SEK28.24
-640%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of AddLife is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for AddLife's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are AddLife's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OM:ALIF BTA B PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in SEK SEK5.35
OM:ALIF B Share Price ** OM (2019-02-20) in SEK SEK209
Europe Life Sciences Industry PE Ratio Median Figure of 18 Publicly-Listed Life Sciences Companies 39.77x
Sweden Market PE Ratio Median Figure of 322 Publicly-Listed Companies 16.21x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of AddLife.

OM:ALIF BTA B PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OM:ALIF B Share Price ÷ EPS (both in SEK)

= 209 ÷ 5.35

39.07x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AddLife is good value based on earnings compared to the Europe Life Sciences industry average.
  • AddLife is overvalued based on earnings compared to the Sweden market.
Price based on expected Growth
Does AddLife's expected growth come at a high price?
Raw Data
OM:ALIF BTA B PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 39.07x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Life Sciences Industry PEG Ratio Median Figure of 10 Publicly-Listed Life Sciences Companies 2.36x
Sweden Market PEG Ratio Median Figure of 228 Publicly-Listed Companies 1.2x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for AddLife, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on AddLife's assets?
Raw Data
OM:ALIF BTA B PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in SEK SEK37.80
OM:ALIF B Share Price * OM (2019-02-20) in SEK SEK209
Sweden Life Sciences Industry PB Ratio Median Figure of 5 Publicly-Listed Life Sciences Companies 10.34x
Sweden Market PB Ratio Median Figure of 561 Publicly-Listed Companies 2.43x
OM:ALIF BTA B PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OM:ALIF B Share Price ÷ Book Value per Share (both in SEK)

= 209 ÷ 37.80

5.53x

* Primary Listing of AddLife.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AddLife is good value based on assets compared to the SE Life Sciences industry average.
X
Value checks
We assess AddLife's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. AddLife has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ALIF BTA B Future Performance

 How is AddLife expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as AddLife has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
14.7%
Expected Life Sciences industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is AddLife expected to grow at an attractive rate?
  • Unable to compare AddLife's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare AddLife's earnings growth to the Sweden market average as no estimate data is available.
  • Unable to compare AddLife's revenue growth to the Sweden market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OM:ALIF BTA B Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 14.7%
Europe Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 8.8%
Sweden Market Earnings Growth Rate Market Cap Weighted Average 8.7%
Sweden Market Revenue Growth Rate Market Cap Weighted Average 4.6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OM:ALIF BTA B Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in SEK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OM:ALIF BTA B Future Estimates Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2019-03-31 2,630 157 1
OM:ALIF BTA B Past Financials Data
Date (Data in SEK Millions) Revenue Cash Flow Net Income *
2018-12-31 2,482 177 129
2018-09-30 2,465 182 125
2018-06-30 2,404 192 123
2018-03-31 2,354 200 117
2017-12-31 2,333 208 120
2017-09-30 2,277 207 129
2017-06-30 2,169 208 125
2017-03-31 2,062 165 122
2016-12-31 1,939 133 112
2016-09-30 1,799 99 90
2016-06-30 1,760 99 82
2016-03-31 1,562 118 78

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if AddLife is high growth as no earnings estimate data is available.
  • Unable to determine if AddLife is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OM:ALIF BTA B Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from AddLife Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OM:ALIF BTA B Future Estimates Data
Date (Data in SEK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2019-03-31 6.39 6.39 6.39 1.00
OM:ALIF BTA B Past Financials Data
Date (Data in SEK Millions) EPS *
2018-12-31 5.35
2018-09-30 5.19
2018-06-30 5.09
2018-03-31 4.83
2017-12-31 4.94
2017-09-30 5.29
2017-06-30 5.11
2017-03-31 5.06
2016-12-31 4.88
2016-09-30 4.13
2016-06-30 3.99
2016-03-31 4.15

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if AddLife will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of ALIF BTA B’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. AddLife's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. AddLife's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess AddLife's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
AddLife has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ALIF BTA B Past Performance

  How has AddLife performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare AddLife's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • AddLife's year on year earnings growth rate has been positive over the past 5 years.
  • AddLife's 1-year earnings growth is less than its 5-year average (7.2% vs 13.3%)
  • AddLife's earnings growth has not exceeded the Europe Life Sciences industry average in the past year (7.2% vs 23.4%).
Earnings and Revenue History
AddLife's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from AddLife Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OM:ALIF BTA B Past Revenue, Cash Flow and Net Income Data
Date (Data in SEK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 2,482.00 129.00 706.00 19.00
2018-09-30 2,465.30 125.30 707.80 18.60
2018-06-30 2,404.30 123.30 699.80 18.60
2018-03-31 2,354.30 117.30 678.80 17.60
2017-12-31 2,333.30 120.30 666.80 17.60
2017-09-30 2,276.60 129.00 634.60 14.90
2017-06-30 2,168.60 125.00 592.60 9.90
2017-03-31 2,061.60 122.00 557.60 5.90
2016-12-31 1,938.60 112.00 527.60 1.90
2016-09-30 1,798.90 89.90 510.60
2016-06-30 1,760.30 82.00 501.10
2016-03-31 1,562.40 77.80 445.80
2015-12-31 1,394.40 78.40 382.60
2015-03-31 1,056.80 80.40 289.00
2014-03-31 983.50 78.00 272.70
2013-03-31 906.50 73.80 258.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • AddLife has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • AddLife used its assets less efficiently than the Europe Life Sciences industry average last year based on Return on Assets.
  • AddLife's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess AddLife's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
AddLife has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ALIF BTA B Health

 How is AddLife's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up AddLife's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • AddLife's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • AddLife's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of AddLife's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from AddLife Company Filings, last reported 1 month ago.

OM:ALIF BTA B Past Debt and Equity Data
Date (Data in SEK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 932.00 846.00 61.00
2018-09-30 784.00 626.00 16.00
2018-06-30 801.00 539.00 11.00
2018-03-31 805.00 518.00 23.00
2017-12-31 748.00 532.70 11.00
2017-09-30 712.00 623.00 17.00
2017-06-30 725.00 567.00 22.00
2017-03-31 737.00 559.00 22.00
2016-12-31 716.90 320.80 14.70
2016-09-30 662.70 254.50 10.70
2016-06-30 678.70 246.80 13.10
2016-03-31 346.60 486.20 11.60
2015-12-31 320.70 698.50 129.80
2015-03-31 263.30 28.10 82.50
2014-03-31 271.60 32.10 76.80
2013-03-31 293.30 28.80 111.40
  • AddLife's level of debt (90.8%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (11.3% vs 90.8% today).
  • Debt is well covered by operating cash flow (20.9%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 16.8x coverage).
X
Financial health checks
We assess AddLife's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. AddLife has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ALIF BTA B Dividends

 What is AddLife's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.05%
Current annual income from AddLife dividends. Estimated to be 1.38% next year.
If you bought SEK2,000 of AddLife shares you are expected to receive SEK21 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • AddLife's pays a lower dividend yield than the bottom 25% of dividend payers in Sweden (1.88%).
  • AddLife's dividend is below the markets top 25% of dividend payers in Sweden (4.86%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OM:ALIF BTA B Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 0.9%
Sweden Market Average Dividend Yield Market Cap Weighted Average of 244 Stocks 3.7%
Sweden Minimum Threshold Dividend Yield 10th Percentile 1.2%
Sweden Bottom 25% Dividend Yield 25th Percentile 1.9%
Sweden Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

OM:ALIF BTA B Future Dividends Estimate Data
Date (Data in SEK) Dividend per Share (annual) Avg. No. Analysts
2019-03-31 2.88 1.00
OM:ALIF BTA B Past Annualized Dividends Data
Date (Data in SEK) Dividend per share (annual) Avg. Yield (%)
2019-02-12 2.200 1.060
2018-05-31 2.200 1.068
2017-05-29 1.500 0.870

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AddLife is not paying a notable dividend for Sweden, therefore no need to check if the payments are stable.
  • AddLife is not paying a notable dividend for Sweden, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of AddLife's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of AddLife's dividends as it is not paying a notable one for Sweden.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess AddLife's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can AddLife afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. AddLife has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ALIF BTA B Management

 What is the CEO of AddLife's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Kristina Willgård
COMPENSATION SEK4,405,000
AGE 53
TENURE AS CEO 4.1 years
CEO Bio

Ms. Kristina Willgård, B.Sc. Econ. M.Sc. Econ. has been Chief Executive Officer and President of AddLife AB since 2015. Ms. Willgård serves as Partner and a Board Member at Willgård AB. She served as the Chief Financial Officer of Addtech AB from September 15, 2010 to November 1, 2015. She served as a Finance Director of Ericsson. She served as the President of Addtech Holding AB. She served as Head of Compliance & Control and Chief Financial Officer at Ericsson AB from 2007 to 2010. Ms. Willgård served as Chief Financial Officer of Netwise from 2005 to 2007 and SWE-DISH Satellite Systems AB from 2003 to 2004. She served as Group Controller and Chief Financial Officer of Frontec AB (now Acando AB) from 2001 to 2003. She served as Business controller of Spendrups and Auditor Arthur Andersen. In addition, her previous assignments in finance and accounting from 1989 to 2001. She serves as Chairman of the Board of AddLife Development AB. She has been a Director of Biolin Scientific Holding AB since 2016. She has been a Director of Serneke Group AB since 2015. She is a Member of the Board of Mediplast AB. She served as member of the Board of Addtech Holding AB. She served as Member of the Board of Envilogg AB and Netwise Sverige AB. Ms. Willgård holds a Bachelor of Science in Business and Economics from the University of Lund in 1989.

CEO Compensation
  • Kristina's compensation has increased by more than 20% in the past year.
  • Kristina's remuneration is about average for companies of similar size in Sweden.
Management Team Tenure

Average tenure and age of the AddLife management team in years:

4.1
Average Tenure
53
Average Age
  • The tenure for the AddLife management team is about average.
Management Team

Kristina Willgård

TITLE
President & CEO
COMPENSATION
SEK4M
AGE
53
TENURE
4.1 yrs

Martin Almgren

TITLE
Chief Financial Officer
AGE
42
TENURE
4.1 yrs

Anders Holmström

TITLE
Business Controller

Jamilah Wass

TITLE
Group Financial Controller
TENURE
1.2 yrs

Lars-Erik Rydell

TITLE
Business Area Manager of Medtech
AGE
63
TENURE
4.1 yrs
Board of Directors Tenure

Average tenure and age of the AddLife board of directors in years:

3.4
Average Tenure
52.5
Average Age
  • The tenure for the AddLife board of directors is about average.
Board of Directors

Johan Sjö

TITLE
Chairman
COMPENSATION
SEK500
AGE
51
TENURE
3.6 yrs

Håkan Roos

TITLE
Director
COMPENSATION
SEK200
AGE
63
TENURE
3.6 yrs

Eva Nilsagård

TITLE
Director
COMPENSATION
SEK200
AGE
54
TENURE
3.2 yrs

Stefan Hedelius

TITLE
Director
COMPENSATION
SEK200
AGE
49
TENURE
3.4 yrs

Birgit Norinder

TITLE
Director
COMPENSATION
SEK200
AGE
70
TENURE
3.4 yrs

Andreas Göthberg

TITLE
Director
AGE
51
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by AddLife insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (SEK) Value (SEK)
19. Feb 19 Buy Johan Sjö Individual 15. Feb 19 15. Feb 19 450 SEK142.00 SEK63,900
X
Management checks
We assess AddLife's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. AddLife has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ALIF BTA B News

Simply Wall St News

ALIF BTA B Company Info

Map
Description

AddLife AB (publ), together with its subsidiaries, provides products, services, and advisory services to private and public sector life science companies in Sweden, Finland, Denmark, Norway, and internationally. The company operates through Labtech and Medtech segments. The Labtech segment provides various products and solutions, including analysis instruments, equipment, microscopes, consumables and reagents, as well as application and technical services primarily to laboratories in medicine, research, academia, food, pharmaceutical, microbiology, clinical chemistry, coagulation, molecular biology, immunology, point-of-care testing, and veterinary diagnostics industries. This segment also offers training programs, seminars, and advisory services. The Medtech segment provides medical device products to various markets, such as surgery, thoracic medicine, neurology, wound care, anaesthesia, intensive care, ear, nose and throat, ostomies, home healthcare, surgical equipment, thoracic surgery, and laboratory. AddLife AB (publ) was founded in 1906 and is headquartered in Stockholm, Sweden.

Details
Name: AddLife AB (publ)
ALIF BTA B
Exchange: OM
Founded: 1906
SEK5,118,057,626
24,488,314
Website: http://www.add.life
Address: AddLife AB (publ)
Birger Jarlsgatan 43,
Box 3145,
Stockholm,
Stockholm County, 103 62,
Sweden
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OM ALIF B Class B Shares OMX Nordic Exchange Stockholm SE SEK 16. Mar 2016
LSE 0REZ Class B Shares London Stock Exchange GB SEK 16. Mar 2016
BATS-CHIXE ALIFBS Class B Shares BATS 'Chi-X Europe' GB SEK 16. Mar 2016
OM ALIF BTA B SER'B'NPV BTA 032019 OMX Nordic Exchange Stockholm SE SEK 14. Feb 2019
Number of employees
Current staff
Staff numbers
873
AddLife employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/02/21 22:59
End of day share price update: 2019/02/20 00:00
Last estimates confirmation: 2018/02/13
Last earnings filing: 2019/02/12
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.